Michael Hellerstein
Dallas VA Medical Center(US)
Publications by Year
Research Areas
Immunotherapy and Immune Responses, SARS-CoV-2 and COVID-19 Research, vaccines and immunoinformatics approaches, HIV Research and Treatment, Mosquito-borne diseases and control
Most-Cited Works
- → A Zika Vaccine Targeting NS1 Protein Protects Immunocompetent Adult Mice in a Lethal Challenge Model(2017)121 cited
- → A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge(2018)48 cited
- → A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge(2019)34 cited
- → A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2(2022)33 cited
- → Comparative studies on in vitro expression and in vivo immunogenicity of supercoiled and open circular forms of plasmid DNA vaccines(2007)27 cited
- → DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent Virus(2016)26 cited
- → VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys(2024)21 cited
- → Dose–response studies for the elicitation of CD8 T cells by a DNA vaccine, used alone or as the prime for a modified vaccinia Ankara boost(2006)21 cited
- → Co-expression of HIV-1 virus-like particles and granulocyte-macrophage colony stimulating factor by GEO-D03 DNA vaccine(2012)20 cited
- → Potent Anti-Delta Effect By a Booster Third-Dose of UB-612, a Precision-Designed SARS-CoV-2 Multitope Protein-Peptide Vaccine(2021)1 cited